Therapeutic Plasma Exchange Market to Grow with a CAGR of 6.75% through 2028
Advances in therapeutic plasma exchange research &
development and expanding variety of therapeutic plasma exchange applications is
expected to drive the Global Therapeutic Plasma Exchange Market growth in the
forecast period, 2024-2028.
According to TechSci Research
report, “Therapeutic Plasma Exchange Market – Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018–2028F” Global Therapeutic Plasma
Exchange Market stood at USD 762.01 Million in 2022 and is anticipated to
project robust growth in the forecast period with a CAGR of 6.75% through 2028.
The expansion of the Therapeutic Plasma Exchange Market can be attributed
to advancements in research and development, an increased prevalence of neurological,
renal, and hematological disorders, and a growing range of therapeutic plasma
exchange applications. The rise in global R&D activities is propelling the
market forward, along with its extensive medical applications. Factors
contributing to market growth include the rising number of clients with
inflammatory illnesses, hematological disorders, cardiovascular diseases, and
the elderly population. Neurological health issues have significantly increased
among the elderly, and the use of cutting-edge techniques like plasma exchange
for treating neurological illnesses is gaining recognition. These elements are
expected to create significant demand opportunities in the global therapeutic
plasma exchange market.
Applications in the treatment of various neurological
illnesses are a major growth driver for the Global Therapeutic Plasma Exchange
Market. Therapeutic Plasma Exchange (TPE) is accepted as a first-line therapy,
either as a stand-alone or in conjunction with other therapies, for
neurological diseases such as acute inflammatory demyelinating
polyradiculoneuropathy, chronic inflammatory demyelinating
polyradiculoneuropathy, myasthenia gravis (MG), and paraneoplastic
encephalopathies. Continuous technological advancements have led to significant
improvements in high-precision methods. This has resulted in enhanced patient
satisfaction and more efficient processing of blood and plasma products. In
comparison to other technologies such as membrane separation methods, this
particular method requires a minimal amount of blood flow. It represents a more
advanced technique that simplifies the process of obtaining blood through the
patient's antecubital or radial veins. Furthermore, these technological
advancements have also enabled more precise control of hydration status,
leading to greater hemodynamic stability during treatment. Ultimately, these
advancements contribute to improved patient comfort, safety, and efficacy in
TPE operations, creating promising opportunities in the market.
The therapeutic plasma market
is experiencing rapid growth due to the increasing prevalence of chronic
conditions worldwide. Moreover, advancements in medical device technology are
driving widespread adoption in hospitals and clinical settings. The growing
preference for therapeutic plasma exchange systems in the treatment of various
chronic conditions is fueling market expansion in both developed and developing
countries. Many manufacturing companies are prioritizing the launch of
cost-effective therapeutic plasma exchange systems to meet the strong demand
from emerging markets.
TPE is also used as
second-line therapy for other neurological diseases, including acute
disseminated encephalomyelitis, chronic focal encephalitis, Lambert-Eaton
myasthenic syndrome, Sydenham’s chorea, natalizumab-associated progressive
multifocal leukoencephalopathy, multiple sclerosis, and neuromyelitis Optica
(NMO, or Devic’s disease), often in combination with other treatments. The increasing
price of apheresis equipment and disposables adds to the overall expense of
apheresis. However, the expanding use of therapeutic plasma transfer for the
treatment of various disorders provides potential growth prospects for market
participants in the future. Therapeutic plasma exchange (TPE) is employed for
treating neurological, hematological, renal, and autoimmune conditions with an
immunological etiology. While therapeutic plasma exchange procedures are
infrequently used in pediatric patients, the increasing number of clinical
trials conducted globally is likely to further expand the market.
The cost of equipment
significantly impacts the adoption of plasma exchange among medical
professionals and, in turn, patients. Apheresis equipment is employed by blood
banks for blood component collection, while hospitals utilize it for
therapeutic plasma exchange procedures. The overall cost of apheresis
treatments is further elevated by the expensive equipment and disposable items.
Browse over XX market data
Figures spread through XX Pages and an in-depth TOC on "Global
Therapeutic Plasma Exchange Market”
The Global Therapeutic Plasma
Exchange Market is segmented into product, technology, indication, end user, regional
distribution, and company.
Based
on indication, the market is segmented into neurological disorders, hematology
disorders, renal disorders, metabolic disorders, and others. The Neurological
disorders segment is projected to generate the highest revenue during the
forecast period. This is attributed to the growing demand for their proven
efficacy in managing neurological conditions such as Guillain-Barre syndrome
(GBS), multiple sclerosis, and myasthenia gravis. In contrast, the
cardiovascular disorders segment is expected to experience the highest growth
rate, driven by the increased adoption of TPE as the primary treatment for
various disorders like arteriosclerosis and rheumatic endocarditis. Moreover,
technological advancements in this segment, expanding the applications of TPE
in the removal of lipoproteins, fibrinogen, inflammatory factors, etc., are
expected to fuel its growth throughout the forecast period.
Based
on region, North America segment is expected to grow during the forecast
period. North America is projected to maintain its dominant position in the
therapeutic plasma exchange systems market throughout the forecast period. This
dominance can be attributed to the global increase in the prevalence of
autoimmune disorders, as well as the growing adoption of lipoprotein apheresis
treatment for cardiovascular conditions such as CAD, hypercholesterolemia,
strokes, and atherosclerosis, which have witnessed a rise in cardiac fatalities
in recent years. For instance, according to The American Heart Association, in
2018, there were approximately 92.1 million individuals in the U.S. affected by
cardiovascular diseases, resulting in a higher demand for TPE and driving
market growth in the region. Furthermore, the availability of advanced
technology and well-established healthcare infrastructures in North America are
expected to contribute to the market's expansion throughout the forecast
period.
Major companies
operating in Global Therapeutic Plasma Exchange Market
are:
- Asahi Kasei Corporation
- Baxter International Inc
- B. Braun Melsungen AG
- Cerus Corporation
- Fresenius Kabi AG
- Haemonetics Corporation
- Hemacare Corporation
- IncMedica S.p.A.
- Kawasumi Laboratories
- Terumo Corporation
Download Free Sample Report
Customers can also request for 10% free customization on
this report.
“The rise in the prevalence of chronic diseases, along with
the increased applications of therapeutic plasma exchange, has led to intensive
research and clinical trials to determine its efficacy compared to other
treatments. These factors are expected to drive market growth during the
forecast period. The myriad uses of therapeutic plasma exchange in treating
neurological, renal, hematological, and metabolic disorders will further propel
the industry in the coming years. Moreover, therapeutic plasma exchange has
proven to be an effective first-line treatment for certain neurological
conditions. This is predicted to significantly enhance the market earnings in
the future. Additionally, the increase in research and development activities
globally is anticipated to stimulate a massive demand for therapeutic plasma
exchange, resulting in substantial expansion of the business in the next
decade. Furthermore, the rise in the number of patients with autoimmune
ailments due to favorable reimbursement policies and healthcare consolidation
will drive market growth. The extensive use of plasma exchange to effectively
manage severe attacks of multiple sclerosis and Guillain-Barre syndrome, as
well as other neurological disorders, will continue to fuel the growth and scope
of the therapeutic plasma exchange market.,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Therapeutic Plasma
Exchange Market Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented By Product (Consumables,
Devices), By Technology (Centrifugation, Membrane Separation), By Indication
(Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic
Disorders, Others), By End User (Blood Collection Centers & Blood Component
Providers, Hospitals & Clinics, Blood Transfusion Centers, Others), By
Region and Competition”, has evaluated the future
growth potential of Global Therapeutic Plasma Exchange Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Therapeutic Plasma Exchange Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com